Want to see HRMY full AI Analyst Report?
HRMY Stock Chart & Stats
$35.32
-$0.48(-1.34%)
At close: 4:00 PM EDT
$35.32
-$0.48(-1.34%)
Day’s Range― - ―
52-Week Range$25.52 - $40.87
Previous CloseN/A
Volume585.34K
Average Volume (3M)836.22K
Market Cap
$2.22B
Enterprise Value$1.69K
Total Cash (Recent Filing)$667.79M
Total Debt (Recent Filing)$153.96M
Price to Earnings (P/E)12.2
Beta1.05
Next Earnings
Nov 03, 2026EPS Estimate
1.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.13
Shares Outstanding58,236,393
10 Day Avg. Volume1,000,961
30 Day Avg. Volume836,219
Financial Highlights & Ratios
PEG Ratio1.74
Price to Book (P/B)2.47
Price to Sales (P/S)2.48
P/FCF Ratio6.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$41.63Price Target Upside17.85% Upside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)3.83
Revenue Forecast (FY)$1.02B
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation And FCFRobust operating cash flow (~$355M TTM) with free cash flow closely matching OCF indicates durable cash conversion. That provides financial flexibility to fund R&D, pursue business development, support commercialization, and absorb shocks across the next several quarters.
High Gross Margins And Earnings PowerSustained high gross margins and recent net income demonstrate strong earnings power from a specialty product model. Even with some margin normalization, structural profitability supports reinvestment and cash harvesting, underpinning stability over a 2–6 month horizon.
Commercial Execution And Market AccessAccelerating patient adds, broad payer coverage and meaningful penetration of diagnosed patients reflect effective commercial execution. This durable access and adoption profile improves revenue visibility and reduces short-term adoption risk across upcoming quarters.
Bears Say
Revenue Concentration On One ProductThe company's earnings are highly concentrated in a single marketed medicine (WAKIX), leaving revenue and cash flow exposed to payer decisions, legal outcomes, or competitive entrants. Limited marketed diversification is a structural vulnerability over multiple quarters.
Rising COGS From Recurring RoyaltiesA structurally higher cost base from new royalty obligations materially reduces gross margin compared with prior years. This recurring expense compresses FCF and limits runway for reinvestment unless revenue growth materially offsets the higher COGS over coming quarters.
ANDA Litigation And Exclusivity RiskOngoing ANDA litigation creates a tangible risk to WAKIX exclusivity and pricing. Legal outcomes could accelerate generic entry or constrain market access, posing a structural threat to revenue that remains unresolved and relevant over the medium-term.
Harmony Biosciences Holdings News
HRMY FAQ
What was Harmony Biosciences Holdings, Inc.’s price range in the past 12 months?
Harmony Biosciences Holdings, Inc. lowest stock price was $25.52 and its highest was $40.87 in the past 12 months.
What is Harmony Biosciences Holdings, Inc.’s market cap?
Harmony Biosciences Holdings, Inc.’s market cap is $2.22B.
When is Harmony Biosciences Holdings, Inc.’s upcoming earnings report date?
Harmony Biosciences Holdings, Inc.’s upcoming earnings report date is Nov 03, 2026 which is in 70 days.
How were Harmony Biosciences Holdings, Inc.’s earnings last quarter?
Harmony Biosciences Holdings, Inc. released its earnings results on Aug 04, 2026. The company reported $1.28 earnings per share for the quarter, beating the consensus estimate of $0.956 by $0.324.
Is Harmony Biosciences Holdings, Inc. overvalued?
According to Wall Street analysts Harmony Biosciences Holdings, Inc.’s price is currently Undervalued.
Does Harmony Biosciences Holdings, Inc. pay dividends?
Harmony Biosciences Holdings, Inc. does not currently pay dividends.
What is Harmony Biosciences Holdings, Inc.’s EPS estimate?
Harmony Biosciences Holdings, Inc.’s EPS estimate is 1.07.
How many shares outstanding does Harmony Biosciences Holdings, Inc. have?
Harmony Biosciences Holdings, Inc. has 58,236,393 shares outstanding.
What happened to Harmony Biosciences Holdings, Inc.’s price movement after its last earnings report?
Harmony Biosciences Holdings, Inc. reported an EPS of $1.28 in its last earnings report, beating expectations of $0.956. Following the earnings report the stock price went up 8.933%.
Which hedge fund is a major shareholder of Harmony Biosciences Holdings, Inc.?
Currently, no hedge funds are holding shares in HRMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Harmony Biosciences Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$41.63 (17.85% Upside)
$41.63 (17.85% Upside)
Blogger Sentiment
Bullish
HRMY Sentiment 88%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 96.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.78%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
23.92%
Trailing 12-Months
Company Description
Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
HRMY Company Deck
HRMY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive commercial and early clinical story: record revenue growth, accelerating patient adds, improved profitability, a strong cash position, and encouraging Phase I PK/safety data for BP‑205 that support once‑daily dosing and potency. Near‑term risks include higher COGS driven by new royalties, pending MAD safety data (insomnia and polyuria reported as transient signals), active ANDA litigation, and enrollment/timing uncertainties for some trials. On balance, the company demonstrated strong execution on revenue and commercialization while delivering promising early BP‑205 data and maintaining ample capital to pursue business development and R&D; remaining near‑term uncertainty centers on upcoming MAD and efficacy readouts and legal outcomes.View all HRMY earnings summariesHRMY Stock 12 Month Forecast
Average Price Target
$41.63
▲(17.85% Upside)
Technical Analysis
Ownership Overview
1.10% Insiders
20.77% Mutual Funds
17.23% Other Institutional Investors
30.30% Public Companies and
Individual Investors